FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CI	HANGES	IN BENE	FICIAL	<b>OWNERS</b>	HIP
• .,			— ——		• • • • • • • • • • • • • • • • • • • •	

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average b	ourden									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Dornan David  (Last) (First) (Middle)  C/O BOLT BIOTHERAPEUTICS, INC.  900 CHESAPEAKE DRIVE				2. Issuer Name and Ticker or Trading Symbol Bolt Biotherapeutics, Inc. [ BOLT ]  3. Date of Earliest Transaction (Month/Day/Year) 02/18/2022						(Ch	Director  Officer (below)	ationship of Reporting Person k all applicable) Director Officer (give title below) Chief Scientific			er ner pecify		
(Street) REDWO CITY (City)	C.		94063 (Zip)	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	e) <mark>X</mark> Form fil	Form filed by One Reporting Person Form filed by More than One Reporting					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3)  2. Transa Date (Month/L				2A. Deemed Execution Date, if any (Month/Day/Yea		Code (			rities Acquired (A) ed Of (D) (Instr. 3, 4		5) Securities Beneficia Owned For Reported Transacti	Securities For Beneficially (C		Direct Indirect B	Nature of idirect eneficial wnership nstr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	erivative   Conversion   Date   Execution Date,   Trecurity   or Exercise   (Month/Day/Year)   if any   Co			5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date of Sec (Month/Day/Year) Under Deriva		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	y D	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisab		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)	11(5)		
Stock Option (Right to Buy)	\$3.08	02/18/2022		A		210,000		(1)	0.	2/17/2032	Common Stock	210,000	\$0.00	210,000		D	

## **Explanation of Responses:**

1. For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2022.

## Remarks:

/s/ William P. Quinn, Attorney-02/23/2022 in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.